A BreastNext multigene panel of 14 genes, excluding BRCA1/2 (ATM, BARD1, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, PALB2, PTEN, RAD50, RAD51C, STK11 and TP53), was used to evaluate hereditary cancer predisposition in 874 patients tested [41]. This evidence concerns the gene PTEN and hereditary cancer.